MedPath

BioGenCell's Personalized Cell Therapy BGC101 Receives FDA Fast Track Designation for Critical Limb Threatening Ischemia

• BioGenCell's BGC101, a personalized cell therapy, has been granted FDA Fast Track Designation for severe Critical Limb Threatening Ischemia (CLTI). • The Fast Track Designation aims to accelerate the clinical development and compassionate-use access for BGC101, addressing the unmet needs of CLTI patients. • BGC101 leverages BioGenCell's TRACT platform, utilizing patient's own immune and stem cells to promote tissue regeneration and improve blood flow. • A Phase 2 clinical trial evaluating BGC101's safety and efficacy in the US, Europe, and Israel has completed patient recruitment, focusing on amputation-free survival.

BioGenCell, an Israeli biotechnology company, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, BGC101, a personalized cell therapy designed to treat severe Critical Limb Threatening Ischemia (CLTI). This designation is intended to expedite the development and review process for drugs that treat serious conditions and fill unmet medical needs, offering hope for patients with limited treatment options.

Addressing Critical Limb Threatening Ischemia (CLTI)

CLTI represents the most advanced stage of peripheral artery disease, characterized by severely reduced blood flow to the extremities, leading to chronic pain, ulcers, and a high risk of amputation and mortality. Many patients with CLTI are not eligible for revascularization procedures, highlighting the urgent need for alternative therapeutic approaches. The current treatment landscape often involves managing symptoms and preventing further disease progression, but effective regenerative therapies are lacking.

BGC101: A Personalized Cell Therapy Approach

BGC101 utilizes BioGenCell's proprietary TRACT platform to create personalized therapies using the patient's own immune and stem cells. This process allows for rapid generation of the cell therapy, typically within one day. The therapy aims to promote tissue regeneration, restore blood flow, and improve limb function in patients with CLTI. Preclinical and early clinical data suggest that BGC101 may offer long-term benefits, with some patients experiencing improvements lasting over seven years after a single treatment.

Clinical Trial Status and Expanded Access

BioGenCell has completed enrollment in a Phase 2 clinical trial evaluating the safety and efficacy of BGC101. This randomized, double-blind study is being conducted at leading medical centers across the United States, Europe, and Israel. The primary endpoints of the trial include amputation-free survival and symptom relief. The Fast Track Designation also enables compassionate-use access for eligible patients, providing them with access to BGC101 while the clinical development program progresses.

Expert Commentary

"Achieving Fast Track Designation is a significant milestone for BioGenCell and for patients in critical need," said Dr. David Raab, Chairman of BioGenCell. Dr. Porat, BioGenCell's Founder and CEO, added, "This recognition underscores the promise of our personalized cell therapy, supported by preliminary clinical results and a clear mechanism of action."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Neuracle Genetics' NG101 Receives FDA Fast Track for Wet AMD Treatment

Neuracle Genetics' NG101, a gene therapy for wet AMD, has been granted Fast Track Designation by the FDA, expediting its development and review process.
NG101 utilizes an AAV-based system to deliver the aflibercept gene, potentially offering a long-term therapeutic effect with a single subretinal injection.

FDA Approves Autolus' CAR-T Cell Therapy Aucatzyl for Relapsed/Refractory B-ALL

The FDA has approved Autolus Therapeutics' Aucatzyl, a CAR-T cell therapy, for treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in adults.
Aucatzyl's approval was based on the FELIX clinical trial, which demonstrated encouraging remission rates and manageable side effects in adult r/r B-ALL patients.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in patients aged 18 months and older.
Kebilidi is the first gene therapy administered directly to the brain to be approved in the United States for this rare genetic disorder.

FDA Grants Fast Track Designation to Genascence's GNSC-001 for Osteoarthritis of the Knee

The FDA has granted Fast Track designation to Genascence's GNSC-001, a gene therapy for osteoarthritis (OA) of the knee, expediting its development and review.
GNSC-001 is designed to provide long-term inhibition of IL-1, a key mediator in OA, through a single intra-articular injection.

Genascence's GNSC-001 Receives FDA Fast Track Designation for Knee Osteoarthritis

Genascence's GNSC-001, a gene therapy targeting IL-1, has been granted Fast Track designation by the FDA for treating knee osteoarthritis.
GNSC-001 aims to provide long-term inhibition of IL-1, a key mediator in osteoarthritis, through a single intra-articular injection.

CD Biopharma's CD-001 Receives FDA Clearance for Phase 1 Trial in Oncology

CD Biopharma's CD-001, a bispecific fusion protein, has been cleared by the FDA for a Phase 1 clinical trial.
CD-001 targets PD-1-positive, CD8-positive T cells using an anti-PD-1 antibody and an engineered IL-21 mutant.

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax for AML

The FDA granted Fast Track designation to ICT01 plus azacitidine and venetoclax for acute myeloid leukemia (AML) treatment in patients unfit for standard induction chemotherapy.
ICT01, a humanized anti-BTN3A monoclonal antibody, selectively activates gamma-delta T cells and is under evaluation in the phase 1/2a EVICTION trial.

BridgeBio's BBP-812 Receives FDA RMAT Designation for Canavan Disease Gene Therapy

BridgeBio Pharma's BBP-812, a gene therapy for Canavan disease, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
The RMAT designation is based on positive Phase 1/2 trial data, showing functional improvements in treated patients and reduced N-acetylaspartate (NAA) levels.

Abata Therapeutics' ABA-101 Treg Therapy Receives FDA Fast Track Designation for Progressive Multiple Sclerosis

Abata Therapeutics' ABA-101, an autologous regulatory T-cell (Treg) therapy, has been granted Fast Track designation by the FDA for progressive multiple sclerosis (MS).
ABA-101 has demonstrated a tolerable safety profile and therapeutic effect in animal models, showing antigen-dependent Treg functionality and anti-inflammatory cytokine production.

NervGen Pharma Receives Fast Track Designation for NVG-291 in Spinal Cord Injury Treatment

NervGen Pharma Corp. has been granted Fast Track designation by the FDA for NVG-291, a novel treatment for spinal cord injury, aiming to expedite its development and review process. The Phase 1b/2a clinical trial is underway, with initial results anticipated by mid-2024.

Reference News

[1]
BioGenCell Receives FDA Fast Track Designation with Expanded Access for BGC101
prnewswire.com · Dec 19, 2024

BioGenCell announced FDA Fast Track Designation for BGC101, its personalized cell therapy for severe Critical Limb Threa...

[2]
BioGenCell Receives FDA Fast Track Designation with Expanded Access for BGC101
morningstar.com · Dec 19, 2024

BioGenCell received FDA Fast Track Designation for BGC101, its lead candidate for treating severe Critical Limb Threaten...

[3]
Israeli startup's personalised cell therapy gets FDA fast-track designation
bignewsnetwork.com · Dec 22, 2024

BioGenCell received FDA Fast Track Designation for BGC101, a personalized cell therapy for severe CLTI. BGC101, using th...

[4]
World News | Israeli Startup's Personalised Cell Therapy Gets FDA Fast-track Designation
latestly.com · Dec 22, 2024

BioGenCell receives FDA Fast Track Designation for BGC101, a personalized cell therapy for severe Critical Limb Threaten...

[5]
BioGenCell Receives FDA Fast Track Designation with Expanded Access for BGC101
finance.yahoo.com · Dec 19, 2024

BioGenCell's BGC101, a personalized cell therapy for severe Critical Limb Threatening Ischemia (CLTI), received FDA Fast...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy